Michael Wolff Jensen

Consejero General en ASCENDIS PHARMA A/S .

Fortuna: 264 412 $ al 30/04/2024

53 años

92 relaciones

Health Technology

Utilities

Consumer Services

Relaciones activas

Nombre	Sexo	Edad	Empresas relacionadas	Colaboración
Jan Mikkelsen	M	65	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S Ascendis Pharma Endocrinology Division A/S Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark. Ascendis Pharma Bone Diseases A/S Ascendis Pharma Growth Disorders AS VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	22 años
Lotte Sønderbjerg	F	62	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S	21 años
An Bang Lu	M	58	VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	6 años
Albert Cha	M	51	ASCENDIS PHARMA A/S	10 años
Peter Rasmussen	M	55	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S	12 años
Lisa Bright	F	56	ASCENDIS PHARMA A/S	7 años
Yi Bo Cao	M	42	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction.	3 años
Dan Dan Dong	M	40	VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	6 años
Kennett Sprogøe	M	46	ASCENDIS PHARMA A/S	17 años
Rasmus Errboe	M	45	ORSTED A/S	12 años
William Fairey	M	60	ASCENDIS PHARMA A/S	2 años
Scott Smith	M	50	ASCENDIS PHARMA A/S	8 años
Martine van Vugt	M	71	GENMAB A/S	23 años
Lars Holtug	M	66	ASCENDIS PHARMA A/S	6 años
Pierre Armand Morgon	M	61	EUROCINE VACCINES AB	11 años
Carl-Johan Dalsgaard	M	68	Vicore Pharma AB Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden.	-
Hong Ni	F	52	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 años
Peng Kuan Chan	M	60	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 años
Zheng Bin Yao	M	58	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 años
Siham Imani	F	47	ASCENDIS PHARMA A/S	2 años
Shan Fu	M	56	VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	6 años
Heidi Hunter	F	66	VICORE PHARMA HOLDING AB	4 años
Jan Nils Sandström	M	86	EUROCINE VACCINES AB	12 años
Melinda Baker	F	-	ASCENDIS PHARMA A/S	-
Hans Jeppsson	M	-	Vicore Pharma AB Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden.	-
Sze Ting Chan	F	42	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	-
Elin Rosendahl	F	-	VICORE PHARMA HOLDING AB	4 años
Birgitte Stephensen	F	63	GENMAB A/S	22 años
Tim Lee	M	-	ASCENDIS PHARMA A/S	-
Anni Lotte Kirstine Pedersen	F	-	Ascendis Pharma Endocrinology Division A/S Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark.	12 años
Jessica Shull	M	-	VICORE PHARMA HOLDING AB	3 años
Stina Singel	M	50	ASCENDIS PHARMA A/S	4 años
Maha Katabi	M	50	Ascendis Pharma, Inc.	-
Jun Yang	M	52	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	4 años
Jun Chen	M	54	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 años
Flemming Steen Jensen	M	63	ASCENDIS PHARMA A/S	9 años

Gráfico relacional

Relaciones con varias empresas

Antiguas relaciones

Nombre	Sexo	Edad	Empresas relacionadas	Colaboración
Rafaèle Elisabeth Tordjman	M	54	ASCENDIS PHARMA A/S	13 años
Thomas Soloway	M	55	ASCENDIS PHARMA A/S	5 años
Birgitte Volck	M	61	ASCENDIS PHARMA A/S	7 años
Michael Blair Widmer	M	76	GENMAB A/S	11 años
Benny Dalgaard Loft	M	59	ORSTED A/S	7 años
Anja Leschly	F	52	VELOXIS PHARMACEUTICALS A/S	-
Tom Vink	M	61	GENMAB A/S	-
Henrik Poulsen	M	57	ORSTED A/S	8 años
Martin Olin	M	55	ASCENDIS PHARMA A/S	4 años
Peter Schøtt Knudsen	M	51	VELOXIS PHARMACEUTICALS A/S	-
Michael Beckert	M	-	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S	12 años
Carsten Krogsgaard Thomsen	M	67	ORSTED A/S	11 años
Bo Kruse	M	52	GENMAB A/S	8 años
Pia Gjellerup	F	65	ORSTED A/S	7 años
Jonathan Silverstein	M	57	ASCENDIS PHARMA A/S	-
James Healy	M	58	ASCENDIS PHARMA A/S	8 años
Thomas Dyrberg	M	69	VELOXIS PHARMACEUTICALS A/S	13 años
Kurt Anker Nielsen	M	78	VELOXIS PHARMACEUTICALS A/S	7 años
Karsten Havkrog Pedersen	M	74	GENMAB A/S	11 años
Thomas A. Larson	M	62	ASCENDIS PHARMA A/S	-
Kathrine Westermann	F	-	ORSTED A/S	-
Rasmus Nagel	M	-	ORSTED A/S	3 años
Rikke Glahn Ren	F	-	GENMAB A/S	-
Dana Pizzuti	M	69	ASCENDIS PHARMA A/S	2 años
Daniel Muthmann	M	-	ORSTED A/S	-
Jorgen Petersen	M	-	GENMAB A/S	-
Marie Olliver	M	-	EUROCINE VACCINES AB	-
Patrick van Berkel	M	55	GENMAB A/S	9 años
Christina Aabo	F	-	ORSTED A/S	10 años
Breian Knudsen	M	-	VELOXIS PHARMACEUTICALS A/S	9 años
Mark Bach	M	67	ASCENDIS PHARMA A/S	-
Rune Róin	M	-	ORSTED A/S	-
Tomas Lykke Nielsen	M	-	ORSTED A/S	-
Sigurd Okkels	M	-	ASCENDIS PHARMA A/S	4 años
Christian Skakkebæk	M	-	ORSTED A/S	10 años
Gérard Soula	M	78	VELOXIS PHARMACEUTICALS A/S	-
Grethe Nørskov Rasmussen	M	62	ASCENDIS PHARMA A/S	11 años
Jytte Koed Madsen	F	71	ORSTED A/S	-
Anders Eldrup	M	76	ORSTED A/S	11 años
Jean Deleage	M	83	VELOXIS PHARMACEUTICALS A/S	-
Lars Rebien Sørensen	M	69	ORSTED A/S	5 años
Martin Auster	M	49	ASCENDIS PHARMA A/S	2 años
Mark Brennan	M	61	ASCENDIS PHARMA A/S	-
Torben Nissen	M	53	ASCENDIS PHARMA A/S	3 años
Edwin de Graaf	M	-	ASCENDIS PHARMA A/S	-
Francesca DeMartino	F	-	VELOXIS PHARMACEUTICALS A/S	-
Jens Kampmann	M	86	ORSTED A/S	7 años
Thomas Dalsgaard	M	58	ORSTED A/S	3 años
Joseph Fred Yospe	M	66	GENMAB A/S	2 años
Paul W. H. I. Parren	M	60	GENMAB A/S	16 años
Lena Birgitta Degling Wikingsson	M	61	EUROCINE VACCINES AB	4 años
Jonathan Leff	M	66	ASCENDIS PHARMA A/S	3 años
Jesper Høiland	M	63	ASCENDIS PHARMA A/S	2 años
Neil Ringdahl	M	-	ASCENDIS PHARMA A/S	-
Karsten Anker Petersen	M	53	ORSTED A/S	-
Niels Svenstrup	M	54	ASCENDIS PHARMA A/S	2 años

Estadísticas

País	Relaciones	% del total
Dinamarca	72	78.26%
China	11	11.96%
Suecia	9	9.78%
Estados Unidos	1	1.09%

Antigüedad de la relación

Activas

Pasados

Hombre

Mujer

Administradores

Ejecutivos

Origen de las relaciones